New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...

A Prescription Drug User Fee Act target date of November 1, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug ...

High-dose docosahexaenoic acid (DHA) supplementation does not yield a change in brain volume or cognitive performance over 24 months, according to a study publi ...

For most people, the risk for serious muscle disorders from statins is low, according to a study published online June 25 in The Lancet. Ting Cai, DPhil, from t ...

Those using upadacitinib had lower risk for discontinuing treatment, regardless of previous exposure to treatment ...

Rituximab noninferior to ocrelizumab for suppressing disease activity on T2-weighted MRI between 6 and 24 months.

The products may now carry a claim telling smokers that switching to ZYN "puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis." ...

Casgevy is the first gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 2 and older.

The 12-month wind-down for therapeutics and 180-day transition for medical devices signal a definitive shift back to standard regulatory pathways, forcing manufacturers like Invivyd to pursue full FDA ...

The FDA released a list of participants for a 2-day July meeting of its Pharmacy Compounding Advisory Committee; at least 7 members have ties to peptide businesses.

When a hospital mistakenly destroyed a patient's placenta despite a signed release form, it faced a lawsuit — and a lesson in what truly constitutes "waste." ...

HbA1c level change from baseline was at least as large with bofanglutide as with semaglutide. HealthDay News — For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 ...